



Regulated information

## Additional Contribution to the Liquidity Contract with ODDO & Cie

**Paris, France, July 7, 2017** – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced an additional contribution of € 300,000 on July 7, 2017, to its liquidity contract held by Oddo Corporate Finance, increasing the total contribution to € 600,000.

In the last half-year report as of June 30, 2017, the following assets appeared on the liquidity account:

- 38,462 GenSight Biologics shares
- € 31,098.55

As a reminder, at the time of its implementation, the following assets appeared on the liquidity account:

- 0 GenSight Biologics share
- € 300,000.00

### Contacts

#### GenSight Biologics

Thomas Gidoin  
Chief Financial Officer  
[tgidoin@gensight-biologics.com](mailto:tgidoin@gensight-biologics.com)  
+33 (0) 6 01 36 35 43

#### RooneyPartners

Media Relations  
Marion Janic  
[mjanic@rooneyco.com](mailto:mjanic@rooneyco.com)  
+1-212-223-4017

#### The Trout Group

Investor Relations  
Chad Rubin  
[crubin@troutgroup.com](mailto:crubin@troutgroup.com)  
+1-646-378-2947

### About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics' lead product candidate, GS010, is in Phase III trials in Leber's Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.